[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,615,672
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,629 M
  • EBITDA $ 4,173 M
  • 60-Month Beta 0.24
  • Price/Sales 4.89
  • Price/Cash Flow 15.79
  • Price/Book 2.23

Options Overview Details

View History
  • Implied Volatility 33.76% (-0.28%)
  • Historical Volatility 28.14%
  • IV Percentile 36%
  • IV Rank 33.08%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 7) 18.22 (2.76%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 163
  • Volume Avg (30-Day) 1,259
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 39,089
  • Open Int (30-Day) 38,538
  • Expected Range 642.29 to 678.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.48
  • Number of Estimates 6
  • High Estimate $11.13
  • Low Estimate $6.29
  • Prior Year $10.72
  • Growth Rate Est. (year over year) -20.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
594.90 +11.03%
on 06/22/26
677.92 -2.57%
on 07/07/26
+58.86 (+9.78%)
since 06/10/26
3-Month
591.52 +11.66%
on 06/02/26
767.21 -13.91%
on 04/23/26
-88.36 (-11.80%)
since 04/10/26
52-Week
541.00 +22.09%
on 10/13/25
821.11 -19.56%
on 01/09/26
+100.75 (+18.00%)
since 07/10/25

Most Recent Stories

More News
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its second quarter 2026 financial and operating results on Thursday,...

REGN : 661.14 (-1.02%)
The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

APGE : 133.68 (+0.08%)
JNJ : 256.68 (-0.93%)
LLY : 1,183.80 (-2.72%)
ABBV : 246.68 (-1.29%)
REGN : 661.14 (-1.02%)
SNY : 43.54 (-0.82%)
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target...

REGN : 661.14 (-1.02%)
3 Profitable Stocks We Think Twice About

3 Profitable Stocks We Think Twice About

AVY : 161.72 (+1.67%)
REGN : 661.14 (-1.02%)
AMCX : 9.60 (-3.03%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK , June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors...

REGN : 661.14 (-1.02%)
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the...

REGN : 661.14 (-1.02%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors...

REGN : 661.14 (-1.02%)
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare...

REGN : 661.14 (-1.02%)
Why Regeneron (REGN) Stock Is Trading Up Today

Why Regeneron (REGN) Stock Is Trading Up Today

REGN : 661.14 (-1.02%)
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky

2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky

MA : 520.41 (-0.53%)
SYK : 330.09 (+0.91%)
REGN : 661.14 (-1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 679.50
2nd Resistance Point 674.33
1st Resistance Point 671.14
Last Price 661.14
1st Support Level 662.78
2nd Support Level 657.61
3rd Support Level 654.42

See More

52-Week High 821.11
Fibonacci 61.8% 714.11
Fibonacci 50% 681.05
Last Price 661.14
Fibonacci 38.2% 648.00
52-Week Low 541.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.